1. Improving outcomes with long-term “destination” therapy using left ventricular assist devices 
James W. Long, MD, PhD, Aaron H. Healy, BS, Brad Y. Rasmusson, MD, Cris G. Cowley, MD, Karl E. Nelson, RN, MBA, Abdallah G. Kfoury, MD, Stephen E. Clayson, MD, Bruce B. Reid, MD, Stephanie A. Moore, MD, Douglas U. Blank, MD, Dale G. Renlund, MD 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 135, Issue 6, Pages (June 2008)
DOI: /j.jtcvs
Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

2. Figure 1
LDSH DT versus REMATCH LVAD. One year post-implant: REMATCH, 52% ± 6%; LDS DT, 77% ± 10%; P = Two years post-implant: REMATCH, 29% ± 6%; LDS DT, 77% ± 10%; P < LDSH, LDS Hospital; LVAD, left ventricular assist device.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions